The present study was designed to examine the Nepicastat effects of light-emitting diode (LED) irradiation on the formation and activity of multinucleated osteoclasts, specifically “”round-shaped”" osteoclast cells (ROC) in different cell types derived from mouse. After 635-nm LED irradiation, the cell viability was evaluated by MTT assay.
The amount of total tartrate-resistant acid phosphatase (TRAP) + osteoclast and the number of ROC cells were also estimated by TRAP solution assay and TRAP staining, respectively. Actin rings were stained with rhodamine-conjugated phalloidin, and resorption assay was performed by dentin slices. In addition, gene expression levels between the control and irradiation groups were evaluated by RT-PCR. In a morphological analysis, the formation of ROC was significantly inhibited by 635-nm LED irradiation in the different
cell types. Actin rings were seen at cell peripheries check details in most ROC cells of the control group, but patches containing disorganized actin were found in the irradiation group. Both the number of ROCs and bone resorption activity were much lower in the irradiation group than in the control group. Also, the gene expression levels involved in actin ring formation such as integrin beta(3) and c-Src decreased in RT-PCR analysis. Overall, 635-nm LED therapy may play a pivotal role in regulating bone remodeling, and it may prove to be a valuable tool to prevent bone loss in osteoporosis and other resorptive bone diseases.”
“Objectives: To (1) investigate physicians’ expectations about community pharmacist’s roles and physician attitudes toward collaborative agreements with community pharmacists in West Virginia and (2) determine physicians’ perceptions of pharmacists providing medication therapy management (MTM) services.
Methods: A mail survey was conducted for a random sample of 500 physicians practicing in West Virginia. Survey items measured the physicians’ perceptions about the roles of pharmacists, their level of comfort with pharmacists providing certain DNA Damage inhibitor MTM services, and their attitudes toward a collaborative agreement
with pharmacists.
Results: 102 responses were received, yielding a response rate of 22.1%; 60% of the physicians had a favorable attitude toward supporting collaborative agreement with pharmacists. Physicians were more comfortable with certain areas of MTM services, such as general drug education and the Medicare Part D prescription drug benefit, and they expected pharmacists to identify medication errors and educate the patients about the safe and appropriate use of medications
Conclusion: Of the physician respondents, 60% reported a favorable attitude toward collaborative practice agreements, but their attitude toward pharmacists’ role in collaborative drug therapy management and pharmacists providing MTM services were not that favorable. Participating physicians may not have consistent expectations regarding pharmacists providing patient care.